奥沙利铂联合恩度介入治疗原发性肝癌疗效观察

目的探讨奥沙利铂联合恩度在未切除的原发肝癌介入治疗中的疗效及不良反应。方法回顾性收集原发肝癌患者99例，其中48例灌注奥沙利铂联合恩度治疗，为联合治疗组。51例仅灌注奥沙利铂治疗，为奥沙利铂组。结果联合治疗组客观缓解率为91％，显著高于奥沙利铂组（74％）（P=0．0024）。经统计学处理发现，奥沙利铂联合恩度灌注法与其客观缓解率有较高相关性，为其相关独立因素（HR=0．18；P=0．012）。而总的不良反应发生率联合治疗组为50％，奥沙利铂组为49％，两组比较无差异（P=0．575）。结论奥沙利铂联合恩度在原发肝癌介入治疗中具有较好疗效且不良反应轻。

The Effect Observation of Oxaliplatin Combined with Rh-endostatin inTransarterial Chemoembolisation of Primary Hepatocellular Carcinoma

ObjectiveTo evaluate the initial safety and efficacy of combination therapy using oxaliplatin plus rh-endostatin for transarterial chemoembolisation(TACE) of unresectable hepatocellular carcinoma(HCC).MethodsPatients who underwent TACE using oxaliplatin plus rh-endostatin(n=48) and control patients who underwent TACE using oxaliplatin-alone(n=51) were included in this study.ResultsThe objective response rate in the oxaliplatin plus rh-endostatin group(91%) was significantly higher than that in the oxaliplatin group(74%,P=0.024).Use of oxaliplatin and rh-endostatin was an independent factor associated with higher objective response rate(hazard ratio=0.18;P=0.012).Overall incidence adverse events was not significantly different between the oxaliplatin plus rh-endostatin group(50%) and the oxaliplatin group(49%,P=0.575).ConclusionTACE using oxaliplatin plus rh-endostatin was associated with an increased objective response rate and comparable adverse effects compared to TACE using oxaliplatin-alone.